Ashkon Software



CLSN - Celsion Corporation

Celsion Corporation logo Celsion Corporation (CLSN) is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. The company's lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is being developed for the treatment of liver cancer.

ThermoDox is designed to release the chemotherapy drug doxorubicin specifically within the tumor, using heat generated by a non-invasive ultrasound device. This approach is intended to enhance the efficacy of doxorubicin while minimizing its toxic effects on healthy tissues.

In addition to ThermoDox, Celsion Corporation is also developing GEN-1, an immunotherapy product candidate that is being studied in combination with standard chemotherapy for the treatment of ovarian cancer. GEN-1 is designed to stimulate the immune system to attack cancer cells, while also enhancing the effects of chemotherapy.

Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey. The company has a small team of employees and collaborates with academic and industry partners to advance its drug development programs. As of 2021, the company is focused on advancing ThermoDox and GEN-1 through clinical trials and seeking regulatory approval for these drugs. Celsion Corporation faces significant competition from other companies developing cancer therapies, particularly in the areas of immunotherapy and targeted




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer